Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › ABVX

SILVERARC CAPITAL MANAGEMENT, LLC position in ABVX

ABIVAX SA · Health Care

SILVERARC CAPITAL MANAGEMENT, LLC reported holding 175,699 shares of ABVX (ABIVAX SA) in its Q3 2026 13F filing — a position valued at US$17.4M, representing 2.22% of its reported portfolio and ranking #14 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ABVX holdings in 10 of the last 11 reported quarters, going back to Q1 2024.

Latest position (Q3 2026)175.70K sh
Reported value held$17.40M
Portfolio Weight2.22%
First reportedQ1 2024
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How SILVERARC CAPITAL MANAGEMENT, LLC's ABVX position evolved

SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in ABVX in Q1 2024 at 75,000 shares (US$1.1M). The position peaked in Q4 2025 at 422,193 shares, worth US$56.9M. Across 10 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 175,699 shares valued at US$17.4M — an increase of 125,699 shares quarter over quarter.. Notable position changes include a 508% increase in Q2 2024 (shares fell 13% over the following quarter), a 83% trim in Q2 2026 (shares fell 26% over the following quarter), a 251% increase in Q3 2026 (shares fell 12% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 75.00K $1.07M New
Q2 2024 455.80K $6.03M Add
Q3 2024 461.66K $5.32M Add
Q4 2024 285.12K $2.09M Reduce
Q1 2025 210.90K $1.32M Reduce
Q3 2025 539.70K $45.82M New
Q4 2025 422.19K $56.93M Reduce
Q1 2026 302.53K $33.69M Reduce
Q2 2026 50.00K $6.66M Reduce
Q3 2026 175.70K $17.40M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABVX and 13F data

ABVX (ABIVAX SA) is a Health Care company. 70 other funds we track also report a position in ABVX — the largest reported positions include TCG Crossover Management, LLC (US$800.6M), Helikon Investments Ltd (US$418.2M), Darwin Global Management, Ltd. (US$348.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABVX

All ABVX fund holders →

FAQ

How long has SILVERARC CAPITAL MANAGEMENT, LLC held ABVX?

SILVERARC CAPITAL MANAGEMENT, LLC has disclosed ABVX holdings in 10 of the last 11 reported quarters, going back to Q1 2024.

What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in ABVX?

As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 175.70K shares of ABVX (ABIVAX SA), valued at $17.40M, representing 2.22% of its reported portfolio and ranking #14.

Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling ABVX?

In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in ABVX. The position peaked in Q4 2025 at 422.19K shares.

Which other funds hold ABVX?

Other major institutional holders of ABVX include TCG Crossover Management, LLC, Helikon Investments Ltd, Darwin Global Management, Ltd., among 70 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.